Recently, Bao Jianbin, member of the Standing Committee of the CPC Kunming Municipal Committee and vice mayor of Kunming, led the party and government delegation of Kunming to visit Beijing Dongfang Baitai Biotechnology Co., Ltd. They conducted in-depth research on the production, operation and technological innovation of enterprises and held symposiums for cordial exchanges.

In order to earnestly implement the spirit of the 13th Plenary Session of the 9th Yunnan Provincial Party Committee and the 11th Municipal Party Congress, comprehensively promote the implementation of Kunming's 13th Five Year Plan, and promote the development of health and bio industry. The party and government delegation of Kunming, led by Bao Jianbin, member of the Standing Committee of Kunming Municipal Committee, vice mayor of Kunming, Chang Shuqi, member of the Standing Committee of Kunming Municipal Committee, Xu Jin, deputy director of the Administrative Committee of Dianzhong New Area in Yunnan, went to Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as " Dongfang Baitai "), a key bio industry enterprise, for research and guidance.

Sheng Licheng, Deputy Director of the Management Committee of Yizhuang Development Zone, Wang Yanwei, Director of the Investment Promotion Bureau of the Development Zone, Lou Mei, Deputy Director of the Development Zone, accompanied the inspection. Bai Xianhong, Chairman of Dongfang Baitai, and Bai Yi, General Manager of Dongfang Baitai warmly welcomed the delegation together with the staff of the company.

At the symposium, Bai Yi, General Manager of Dongfang Baitai, reported on the latest achievements, future development goals and work deployment of the company. The current situation of antibody drug development at home and abroad and the important role played by Dongfang Baitai in the field of innovative antibody drug research were emphatically introduced.

Manager Bai introduced that the development of the global biopharmaceutical industry is currently in a fast rising period. Antibody drugs and biological vaccines are considered as "potential stocks" for the future development of biological medicine. Driven by the 13th Five Year Plan for the pharmaceutical and biological industry, China's antibody drugs will usher in a period of development opportunities.

The antibody has the characteristics of high specificity and high affinity. It makes that it show incomparable advantages of other types of drugs in the diagnosis and treatment of diseases. Antibody drugs have great market potential in China. However, due to the late start of the development of antibody drugs in China, there are few domestic varieties on the market, and most of them are imported varieties that are widely used in clinical practice. In addition, most of the varieties that have officially entered the registration process in China are imitations, and there is a shortage of innovative varieties.

Dongfang Baitai seized the opportunity to promote the rapid development of the biological industry, followed the national policy, catered to the market demand, increased investment, and was enthusiastic and energetic in innovation. The company now has more than 20 Chinese invention patents. There are many international patents. It covers 18 countries and regions including the United States, Europe, Japan, South Korea and Eurasia. More than 40 registered trademarks have been approved.

The company's JY09 project for the treatment of type II diabetes is a "triple" project supported by the national key new drug development. At present, Phase I clinical study is under way. It is expected to obtain a new drug certificate in 2021. It has obtained Chinese patent authorization. International patents have been granted by the United States, the European Union, Japan, South Korea, Eurasia, Brazil, India and other countries.

After the symposium, the delegation showed great interest in antibody drug development. They went deep into the antibody drug research and development laboratory. They understand the operation of innovative antibody drug screening platforms and other research and development platforms, as well as the development and production process of biological antibody drugs. The delegation visited the company's antibody library, molecular biology and quality laboratory. In front of the innovative antibody research and development platform, high-end precision instruments and equipment and general manager Bai Yi's detailed explanation, the leaders expressed their admiration. They also fully affirmed the company's innovative monoclonal antibody drug research and development strength.

The delegation leaders commended Dongfang Baitai's achievements in the field of innovative antibody drug development. They fully affirmed the company's efforts and contributions to the development of China's bio pharmaceutical industry. At the same time, the delegation welcomes innovative enterprises like Dongfang Baitai to settle down in Kunming, continue to expand the R&D and production scale, further refine, expand and strengthen, and benefit the people of the country.